Skip to content

ET-blockade and Exercise-induced Vascular Adaptations in T2DM

Effect of a Dual ET(Endothelin)-Blocker on Exercise Induced Vascular Adaptations in Type 2 Diabetes Mellitus (T2DM)

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01779609
Enrollment
19
Registered
2013-01-30
Start date
2010-04-30
Completion date
2013-12-31
Last updated
2016-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Brief summary

The purpose of this study is to establish the effect of ET blockade on vascular adaptations during an 8-week exercise program in subjects with T2DM. We hypothesize that combining ET - blockade with exercise training leads to an acute increase of exercise induced blood flow when compared with exercise alone. We expect that this will lead to an optimization of vascular training effect in T2DM.

Interventions

DRUGBosentan
DRUGPlacebo
BEHAVIORALExercise

Supervised exercise training program of 8 weeks, for 3x/week

Sponsors

Actelion
CollaboratorINDUSTRY
Radboud University Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
MALE
Age
40 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Type 2 Diabetes Mellitus (\>2 years since diagnosis) OR controls

Exclusion criteria

* \<40 years of age * \>65 years of age * smoking * cardiovascular disease * diabetes related manifest vascular complications * Type 1 Diabetes Mellitus * use of Glibenclamide * use of HIV drugs * use of calcineurin inhibitors * use of drugs that interfere with CYP3A4 and CYP2C19

Design outcomes

Primary

MeasureTime frame
Flow mediated dilation8 weeks

Secondary

MeasureTime frame
Conduit Artery Dilator Capacity8 weeks
Intima-Media Thickness8 weeks
Maximal Oxygen Uptake8 weeks

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026